Acute Pancreatitis Pipeline Analysis Report 2026

Report Coverage

The Acute Pancreatitis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into acute pancreatitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for acute pancreatitis. The acute pancreatitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The acute pancreatitis Pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with acute pancreatitis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to acute pancreatitis.

Read more about this report - Request a Free Sample

Acute Pancreatitis Pipeline Outlook

Acute pancreatitis is a sudden inflammatory condition of the pancreas characterized by premature activation of digestive enzymes within pancreatic tissue, leading to pancreatic injury and inflammation. It commonly occurs due to gallstones, excessive alcohol consumption, hypertriglyceridemia, or metabolic disturbances. The condition can cause severe abdominal pain, systemic inflammatory response, pancreatic necrosis, and, in severe cases, multi-organ dysfunction, requiring prompt medical intervention.

Acute pancreatitis treatment focuses on fluid resuscitation, pain management, nutritional support, and the prevention of complications. Advanced approaches include pancreatic enzyme therapy, investigational IL-6 Inhibitors, and targeted interventions aimed at organ failure prevention and reducing systemic inflammation in high-risk patients. In February 2026, CalciMedica reported positive results from the CARPO clinical trial evaluating Auxora (zegocractin), a calcium release-activated calcium channel inhibitor for Acute Pancreatitis. The study demonstrated improved recovery outcomes, reduced pancreatic necrosis, and enhanced prevention of organ failure, highlighting its potential alongside fluid resuscitation protocols and emerging targeted therapies for severe disease management.

Acute Pancreatitis Epidemiology

The pipeline reflects a growing need for innovative therapies due to the increasing disease burden worldwide. According to Qadri, Rateeba et al. (2026), acute pancreatitis has a significantly higher mortality burden in the United States, with a mean age-adjusted mortality rate of 4.34 per 100,000 population. Additionally, as per Ajith K. Siriwardena et al. (2026), the incidence of acute pancreatitis in the United Kingdom is estimated at 56 cases per 100,000 people, with global incidence continuing to rise. This increasing patient population, coupled with severe complications such as organ failure and pancreatic necrosis, is driving investment in drug development, clinical trials, and the acute pancreatitis treatment pipeline.

Acute Pancreatitis – Pipeline Therapeutic Assessment

Acute Pancreatitis Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 36%, covers a major share of the total acute pancreatitis clinical trials, reflecting strong clinical advancement and supporting the development of effective treatment options. It is followed by phase IV at 25%, highlighting ongoing post-marketing evaluation and real-world evidence generation. Phase III accounts for 17%, with phase I at 14%, while early phase I represents 8%, demonstrating sustained innovation and supporting long-term market growth.

Acute Pancreatitis Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the acute pancreatitis pipeline analysis include monoclonal antibodies, small molecules, and peptide. The acute pancreatitis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for acute pancreatitis. Calcium release-activated calcium (CRAC) channel inhibitors are emerging as a promising drug class in the acute pancreatitis drug pipeline, targeting excessive inflammation and preventing organ damage. For instance, Auxora™ (CM4620), developed by CalciMedica, is currently under clinical evaluation for acute pancreatitis with systemic inflammatory response syndrome (SIRS). The therapy selectively inhibits Orai1-containing CRAC channels, helping reduce inflammatory responses, improve solid food tolerance, lower the risk of severe organ failure, and shorten hospitalization duration, thereby supporting advancements in acute pancreatitis treatment and pancreatic inflammation management.

Acute Pancreatitis Clinical Trials – Key Players

The EMR report for the acute pancreatitis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed acute pancreatitis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in acute pancreatitis clinical trials:

• Arrowhead Pharmaceuticals
• Panafina, Inc.
• CalciMedica, Inc.
• Fujian Shengdi Pharmaceutical Co., Ltd.
• Alcresta Therapeutics, Inc.
• GeneCradle Inc.
• CorrectSequence Therapeutics Co., Ltd.
• SCM Lifescience Co., Ltd.
• Pfizer
• Regeneron Pharmaceuticals

Acute Pancreatitis – Emerging Drugs Profile

Key Questions Answered in the Acute Pancreatitis Pipeline Insight Report

• Which companies/institutions are leading the acute pancreatitis drug development?
• Which company is leading the acute pancreatitis pipeline development activities?
• What is the current acute pancreatitis commercial assessment?
• What are the opportunities and challenges present in the acute pancreatitis pipeline landscape?
• What is the efficacy and safety profile of acute pancreatitis pipeline drugs?
• Which company is conducting major trials for acute pancreatitis drugs?
• Which companies/institutions are involved in acute pancreatitis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in acute pancreatitis?

Reasons To Buy This Report

The acute pancreatitis pipeline analysis report provides a strategic overview of the latest and future landscape of treatments for acute pancreatitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into acute pancreatitis collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Pancreatic Cancer Drug Pipeline Analysis Report

Pancreatic Cancer Market